Glucovision® ([F-18]-FDG)

[F-18]-Fludeoxyglucose Injection, (“[F-18]-FDG”) is one of the most widely distributed molecular imaging agents in Canada. Used in combination with positron emission tomography (PET), Glucovision enables physicians to non-invasively detect and stage isolated pulmonary nodules and non-small cell lung cancer. PET imaging centres throughout Canada trust CPDC for reliable, daily deliveries of Glucovision.

Description

Sterile Solution for Injection

1 – 540 GBq [F-18]-FDG per vial (Glucovision® Phosphate)
1 – 453 GBq [F-18]-FDG per vial (Glucovision® Citrate)

Indications and Clinical Use

Glucovision® ([F-18]-FDG Injection) is indicated for use with positron emission tomography in the following:

– Differential diagnosis of isolated indeterminate pulmonary nodules.

– Staging of non-small cell lung cancer.

– Detection of residual or recurrent mass after initial non-small cell lung cancer therapy.

Contraindications

Patients who are hypersensitive to this drug or to any ingredient in the formulation or component of the container.  For a complete listing, see the Dosage Forms, Composition and Packaging section of the product monograph.

Serious Warnings and Precautions

Glucovision® should be used only by those health professionals who are appropriately qualified in the use of radioactive prescribed substances in or on humans.

Glucovision® should not be administered to pregnant women unless it is considered that the benefits to be gained outweigh the potential hazards to the fetus.

Glucovision® is excreted in human breast milk. To avoid unnecessary irradiation of the infant, formula feeding should be substituted temporarily for breast feeding.

Availability

Monday – Saturday. CPDC delivers to all major Canadian markets on a daily basis. Contact us for the specific availability in your region within Canada.

Canadian Product Monograph

Product Monograph

For more information contact us at: